Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of Nasalfent for breakthrough cancer pain
2006-005403-34Phase 3Completed
- Sponsor
- Archimedes Development Ltd
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fentanyl in breakthrough cancer pain (BTcP) and cancer pain, sponsored by Archimedes Development Ltd. Primary endpoint: Adverse events. Started Nov 2006; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)cancer pain
Beyond the preview
Go deeper on 2006-005403-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005403-34.